Literature DB >> 28882090

Stenosis length of middle cerebral artery and branch atheromatous disease associated infarct.

Jian Wang1, Yujie Wang1, Zijia Chai1, Yue Xin1, Jialiang Wang1, Jianting Qiu1.   

Abstract

BACKGROUND: We analyzed the relationship between the characteristics of branch atheromatous disease associated infarct (BAI) and stenosis length (SL) of relevant middle cerebral artery (MCA) M1 segment.
METHODS: Ninety-five patients with BAI were recruited from 1024 consecutive acute ischemic stroke patients. Among them, 59 patients (62.11%) had concurrent relative stenosis of MCA M1 segment. The neurologic deficit severity at admission was assessed by National Institutes of Health Stroke Scale (NIHSS) and the infarct size by infarct lesion thickness and maximum diameter. The SL and the distance from the carotid terminal segment to stenosis (DT) were measured on coronary projection on 3D TOF MRA. The correlations between SL and NIHSS, SL and infarct lesion maximum diameter were analyzed.
RESULTS: There was no difference between BAI patients with or without M1 stenosis in image markers for infarct etiological subtype. SL was significant difference in patients with NIHSS >3 vs. ≤ 3 (p = 0.032) at admission. Further analysis showed that SL correlated with NIHSS at admission (rs = 0.613, p = 0.000) and maximum diameter (rs = 0.621, p = 0.000) significantly.
CONCLUSION: SL is a significant moderate predictor for infarct lesion diameter and neurologic deficit severity.

Entities:  

Keywords:  Branch artery disease; early neurologic deterioration; middle cerebral artery stenosis; neurologic deficit severity; stenosis length

Mesh:

Year:  2017        PMID: 28882090     DOI: 10.1080/00207454.2017.1377710

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  1 in total

1.  Association between fasting blood glucose and intracranial cerebral artery stenosis: a secondary analysis based on a retrospective cross-sectional study in Korean adults.

Authors:  Dan Wu; Danghan Xu; Fan Ye; Nuo Xu; Taotao Yao; Muxi Liao
Journal:  Acta Diabetol       Date:  2021-02-08       Impact factor: 4.280

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.